Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (June 2026)
23 slides from Revelation Biosciences's investor presentation, June 2026
Slide 1: Innovative Solutions for Acute and Chronic Disease
Innovative Solutions for Acute and Chronic Disease Corporate Presentation NASDAQ: REVB June 2026 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: Why Invest In Revelation Biosciences?
Why Invest In Revelation Biosciences? • Lead drug candidate (Gemini) for acute kidney injury Significant Market Significant long-term value building for treatment of acute and chronic disease driven by dysregulated inflammation • Substantially derisked Strong mechanistic rationale Solid clin
Slide 4: Our Programs
Our Programs Program* (Indication) Significant Unmet Need Next Clinical Milestone Lead Program • ~50% of all ICU patients develop AKI (20% of all GEM-AKI hospitalized)1 Phase 2/3 Pivotal Study (Acute Kidney Injury) • 3.2 Million patients • $5.0 Billion market potential Value-Building • 10% of US pop
Slide 5: AKI
AK| 2 REVELATION BIOSCIENCES
Slide 6: AKI is a Significant Problem
AKI is a Significant Problem • Acute Kidney Injury (AKI) is a sudden loss of kidney function ~50% of all ICU patients develop AKI (20% of all hospitalized)1 Severe AKI (stage 3) requires the need for dialysis leading to longer recovery times and significantly higher mortality (>50%) Renal repl
Slide 7: Conservatively, AKI is a $5 Billion Market
Conservatively, AKI is a $5 Billion Market Cost Burden3 $21,250 (Current Standard of Care) Total Hospital Admissions1 34,426,650 All-Cause AKI Incidence2 Treatment Price 6,885,330 $10,625 (Target Price = 50% Cost Savings) AKI Stage 2/32 2,341,012 Market Penetration Annual Market Potential 468,202 $5
Slide 8: Potential Future Applications Using Gemini – a Significant Opportunity
Potential Future Applications Using Gemini – a Significant Opportunity Neurodegenerative Diseases • Parkinson's • Alzheimer's Disease Cardiovascular Disease • Myocarditis • Pericarditis Hepatic Disease • Cardiorenal Syndrome • MASH • IgA Nephropathy Renal Disease • Chronic Kidney Disease • IgA Nephr
Slide 9: How Gemini Works
How Gemini Works BIOSCIENCES
Slide 10: Gemini Activates the TRIF Pathway to Resolve Inflammation
Gemini Activates the TRIF Pathway to Resolve Inflammation The Inflammatory Cycle is Self-Propagating Gemini Reduces Inflammation by Breaking the Inflammatory Cycle 10
Slide 11: Gemini Activates TRIF Pathway in Both Humans and Animals
Gemini Activates TRIF Pathway in Both Humans and Animals Cytokine Upregulation in Humans (Phase 1 study data in healthy volunteers) IL1-RA IL-10 NGAL Neutrophil Cytokine Upregulation in Healthy Animals IL1-RA IL-10 NGAL Neutrophil 11
Slide 12: Gemini Reduces Inflammation and Restores Immunocompetence in Patients
Gemini Reduces Inflammation and Restores Immunocompetence in Patients1 Background cytokine levels pre and post dose2 Cellular responsiveness to LPS stimulation pre and post dose3 • Gemini significantly and durably reduces the number of • Gemini effectively restored immunocompetence elevated inflamma
Slide 13: Gemini significantly reduced fibrotic scarring in an inflammatory kidney model
Gemini significantly reduced fibrotic scarring in an inflammatory kidney model1 Gemini significantly reduced tissue scarring Antifibrotic activity of Gemini driven (new collagen deposition)2 by changes in key cytokines • Daily dosing with Gemini significantly reduced renal • Gemini treatment induced
Slide 14: Gemini Imparted Significant Protection in an AKI Model
Gemini Imparted Significant Protection in an AKI Model1 Gemini significantly reduced serum creatinine (A)2 and neutrophilic infiltration (B)3 A. B. Gemini significantly reduced cortical (C) and medullary (D) tubular necrosis C. D. 1 The ischemic reperfusion injury (IRI) model is used to study AKI, G
Slide 15: Pivotal Study
Pivotal Study BIOSCIENCES
Slide 16: Gemini Phase 2/3 Pivotal “TITAN” Study
Gemini Phase 2/3 Pivotal “TITAN” Study1,2 Phase 2: • 185 Severe stage 2 or stage 3 acute kidney injury patients not yet on dialysis will be administered Gemini or placebo. • Multiple dosing regimens will be evaluated • Estimated Start: Q4 2026 Adaptation (a seamless transition to Phase 3): • The saf
Slide 17: The Team
The Team BIOSCIENCES
Slide 18: Experienced Management
Experienced Management Experienced management Successful track record in A history of building Management has broad and scientific team multiple startups and turn- successful commercial experience in financings and arounds including organizations investor relations Extensive product development expe
Slide 19: AKI Scientific Advisory Board
AKI Scientific Advisory Board Member Role Specialty Laurence Busse, MD, MBA, FCCM Lead Principal Investigator • Critical Care Nephrologist • Medical Director for critical care at Emory Johns Creek Hospital Sean Bagshaw, MD, MSc, FRCPC Scientific Advisor • Clinician Scientist/ Critical Care Nephrolog
Slide 20: What the Docs are Saying
What the Docs are Saying • “I am honored to serve as Principal Investigator for this important study and to collaborate closely with the team at Revelation Biosciences,” said Laurence Busse, MD, MBA, FCCM. “Acute kidney injury remains a significant unmet need in critical care, and there is a clear n
Slide 21: Financials
Financials BIOSCIENCES
Slide 22: Financial Overview
Financial Overview Key Financial Summary 3/31/2026 Beneficial Holders Shares % Cash $14,113,415 Armistice Capital 323,241 8.3 Stockholders Equity $12,988,953 Management 187,280 4.8 Cash Used for Operations $3,214,851 Total 510,521 13.1 Cash Provided by Financing $6,699,814 Cap Table Shares Common St
Slide 23: Thank You!
Thank You! For more information, please visit www.revbiosciences.com 23
Revelation Biosciences — Investor Presentation (June 2026) on 6ix